Comparison of characteristics of solution and conventional reactors for 99Mo production

Nearly all the 99mTc administered to patients is obtained from eluting a radionuclide generator. The generators manufactured by the US radiopharmaceutical companies use only the high-specific activity molybdenum produced by the fission of uranium. The dominant production methods are those used by Cintichem, Inc. and Nordion International. There are, however, competing methods of the production of fission-based 99Mo. One of the most promising proposed alternatives is the use of solution reactors (or homogeneous reactors). The operational characteristics of conventional reactors (i.e., Cintichem process) and those of solution reactors to produce 99Mo for use in manufacturing 99Mo/99mTc generators are examined. The use of conventional reactors has the disadvantage of generating large amounts of radioactive waste. The use of solution reactors can significantly reduce this problem. Both methods require rigorous processing to meet the purity requirements due to the presence of fission product contamination